Roche's Actemra/RoActemra (tocilizumab) Receives the US FDA's Approval as the First Biologic for Systemic Sclerosis-Associated Interstitial Lung Disease
Shots:
- The approval is based on P-III focuSSced trial assessing Actemra (SC- 162mg) vs PBO in a ratio (1:1) in 212 adults with SSc. The data from P-I/II fascinate study also supported the approval
- The P-III study did not meet its 1EPs i.e. change from baseline @48wks. in mRSS. In subgroup patients- decline in mean ppFVC (0.07% vs -6.4%-); change in mRSS (-5.88 vs -3.77)
- In general- the therapy reduced the rate of progressive loss of lung function in people with SSc-ILD. Actemra is the 1st FDA approved therapy and had received PRD for the treatment of SSc-ILD
Ref: Roche | Image: Roche
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com